Changes in vascular alpha1- and alpha2-adrenoceptor responsiveness by selegiline treatment

Fundamental and Clinical Pharmacology

Volumn 15, Issue 4, 2001, Pages 239-245

  Pelat, M ^a   Verwaerde, P ^a   Tran, M A ^a   Berlan, M ^a   Senard, J M ^a   Montastruc, J L ^a  

^a INSERM   (France)

Author keywords

Alpha1 adrenoceptor responsiveness; Alpha2 adrenoceptor responsiveness; Noradrenaline; Selegiline; Yohimbine

Indexed keywords

2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; MONOAMINE OXIDASE B INHIBITOR; NORADRENALIN; PHENYLEPHRINE; PRAZOSIN; PROPRANOLOL; SELEGILINE; YOHIMBINE; MONOAMINE OXIDASE INHIBITOR;

ADRENERGIC STIMULATION; ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; BLOOD VESSEL COMPLIANCE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOG; DOSE RESPONSE; FOURIER TRANSFORMATION; HEART RATE; LOW FREQUENCY NOISE; MALE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PHARMACOEPIDEMIOLOGY; PRESSOR RESPONSE; PRIORITY JOURNAL; SPECTROSCOPY; SYSTOLIC BLOOD PRESSURE; ANIMAL; BLOOD; BLOOD PRESSURE; DRUG EFFECT; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

ADMINISTRATION, ORAL; ANIMALS; BLOOD PRESSURE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; MALE; MONOAMINE OXIDASE INHIBITORS; MUSCLE, SMOOTH, VASCULAR; NOREPINEPHRINE; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2; SELEGILINE; YOHIMBINE;

EID: 0034740821     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2001.00036.x     Document Type: Article

References (39)

1. A review of the pharmacology of selegiline
2. Pharmacology of selegiline
3. Role of selegiline in combination therapy of Parkinson's disease
4. Effects of tocophenol and Deprenyl on the progression of disability in early Parkinson's disease
5. Investigation by Parkinson's disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early mild Parkinson's disease: Further results of randomized trial and confidential inquiry
6. Mortality in people taking selegiline: Observational study
7. Effect of selegiline on mortality in patients with Parkinson's disease
8. Autonomic effects of selegiline: Possible cardiovascular toxicity in Parkinson's disease
9. Selegiline-induced postural hypotension in Parkinson's disease. A longitudinal study on the effects of drug withdrawal
10. Selegiline disminishes cardiovascular autonomic responses in Parkinson's disease
11. Evidence for increase beta-adrenoceptor responsiveness induced by 14 days of simulated microgravity in humans
12. A study of alpha1- and alpha2-adrenoceptor responsiveness in diabetic insipidus dogs
13. Yohimbine. A pharmacological probe for study of the alpha2-adrenoceptor
14. Changes in plasma catecholamine and neuropeptide Y levels after sympathetic activation in dogs
15. Effects of yohimbine, an alpha2-adrenoceptor antagonist, on experimental neurogenic orthostatic hypotension
16. Changes in spontaneous behavior in the dog following oral administration of L-Deprenyl
17. The effect of L-Deprenyl on behavior, cognitive function, and biogenic amines in the dog
18. The pharmacokinetics and absolute bioavailability of selegiline in the dog
19. Effects of chronic oral administration of L-Deprenyl inthe dog
20. Role of the autonomic nervous system in blood pressure and heart rate variability in rats: A spectral analysis approach
21. Low frequency components of cardiovascular variabilities markers of sympathetic modulation
22. Spectral analysis of blood pressure and heart rate, catecholamine and neuropeptide Y plasma levels in a new model of neurogenic orthostatic hypotension in dog
23. Power spectral analysis of heart rate and blood pressure variability in anaesthetized dogs
24. Evaluation of baroreceptor- heart rate reflex by 24th intra arterial blood pressure monitoring in humans
25. Identification of human platelets alpha2-adrenoceptors with a new antagonist [3H] RX821002, a 2-methoxy derivative of idazoxan
26. A rapid sensitive method for the quantitation of protein utilizing the principle of protein dye binding
27. Adverse drug reactions to selegiline. A review of the French pharmacovigilance database
28. Selegiline and catecholamine metabolism
29. o) in the treatment of Parkinson's disease
30. Spectral analysis of sympathetic nerve activity and blood pressure in conscious rats
31. Deprenyl is metabolized to met-amphetamines and amphetamine in man
32. Clinical pharmacology of monoamine oxidase inhibitors
33. Deprenyl. Loss of selectivity for inhibition of B-type MAO after repeated treatment
34. Does the B form selective monoamine oxidase inhibitor loss selectivity by long term treatment?
35. Metabolism of alpha- and beta-adrenergic receptors in vitro and in vivo
36. Reserpine induces vascular alpha2-adrenergic supersensitivity and platelet alpha2-adrenoceptor up-regulation in dog
37. Adrenergic receptor signal transduction and regulation
38. Alpha-adrenergic receptors in hypertension
39. Adrenergic supersensitivity in Parkinsonians with orthostatic hypotension